Trial Profile
A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications Bladder cancer; Cholangiocarcinoma; Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors RedHill Biopharma
- 20 Apr 2017 Results published in a RedHill Biopharma media release.
- 20 Apr 2017 According to a RedHill Biopharma media release, data from this study has been published in Clinical Cancer Research.
- 18 Apr 2017 Results assessing safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of ABC294640, published in the Clinical cancer research: an official journal of the American Association for Cancer Research